{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443319625
| IUPAC_name = 2-(1-Benzofuran-4-yl)-''N''-methyl-''N''-[(5''R'',7''S'',8''S'')-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
| image = Enadoline2d.png
| width = 200

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 124378-77-4
| ATC_prefix = none
| ATC_suffix =
| PubChem = 60768
| IUPHAR_ligand = 1646
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54765
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = KJL283326C
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 318859

<!--Chemical data-->
| C=24 | H=32 | N=2 | O=3
| molecular_weight = 396.52 g/mol
| smiles = O=C(Cc1cccc2occc12)N(C)C1CCC2(CCCO2)CC1N1CCCC1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H32N2O3/c1-25(23(27)16-18-6-4-7-22-19(18)9-15-28-22)20-8-11-24(10-5-14-29-24)17-21(20)26-12-2-3-13-26/h4,6-7,9,15,20-21H,2-3,5,8,10-14,16-17H2,1H3/t20-,21-,24-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JMBYBVLCYODBJQ-HFMPRLQTSA-N
}}

'''Enadoline''' is a drug which acts as a highly selective [[kappa opioid receptor|κ-opioid]] [[agonist]].

In human studies, it produced visual distortions and feelings of [[dissociation (psychology)|dissociation]], reminiscent of the effects of [[salvinorin A]].<ref name="pmid11594439">{{cite journal
|vauthors=Walsh SL, Strain EC, Abreu ME, Bigelow GE |title=Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
|journal=Psychopharmacology
|volume=157
|issue=2
|pages=151–62
|year=2001
|pmid=11594439
|doi=10.1007/s002130100788
}}</ref>

It was studied as a potential [[analgesic]], but abandoned because of the dose-limiting effects of [[dysphoria]], which could be expected from a κ-opioid agonist. There was mention of its potential in treating [[coma]]tose head injury or [[stroke]] victims, where that type of side effect would be immaterial.<ref name="pmid15989506">{{cite journal
|vauthors=Barber A, Gottschlich R |title=Novel developments with selective, non-peptidic kappa-opioid receptor agonists
|journal=Expert Opin Investig Drugs
|volume=6
|issue=10
|pages=1351–68
|year=1997
|pmid=15989506
|doi=10.1517/13543784.6.10.1351
}}</ref>

==Potency==
When enadoline was first reported in 1990, it was "the most potent κ-selective analgesic ever reported ... 25 times more potent than morphine and 17 times more potent than [[U-62066]]".<ref name=halfpenny>{{Cite journal | doi = 10.1021/jm00163a047| pmid = 2153208| title = Highly selective .kappa.-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted cyclohexyl]arylacetamide derivatives| journal = Journal of Medicinal Chemistry| volume = 33| issue = 1| pages = 286–91| year = 1990| last1 = Halfpenny| first1 = Paul R.| last2 = Horwell| first2 = David C.| last3 = Hughes| first3 = John| last4 = Hunter| first4 = John C.| last5 = Rees| first5 = David C.}}</ref>

==References==
{{Reflist|2}}

{{Hallucinogens}}
{{Opioidergics}}

[[Category:Synthetic opioids]]
[[Category:Dissociative drugs]]
[[Category:Pyrrolidines]]
[[Category:Kappa agonists]]
[[Category:Tetrahydrofurans]]
[[Category:Acetamides]]
[[Category:Benzofurans]]
[[Category:Spiro compounds]]
[[Category:Psychedelic drugs]]
[[Category:Abandoned drugs]]


{{Psychoactive-stub}}